文献速递心脑血管急症消化、代谢与肾脏急症

瑞典COVID-19后急性心肌梗死与缺血性卒中风险:自身对照病例系列与匹配队列研究

Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study.
PubMed 文献 · Lancet · 2021-07-29
一句话结论瑞典全国数据显示COVID-19后2周内急性心梗和缺血性卒中风险显著升高,提示需接种疫苗。

该研究在瑞典纳入2020年2月1日至9月14日全部86742例COVID-19患者进行自身对照病例系列分析,并纳入348481名按年龄、性别、居住县匹配的对照进行匹配队列研究。自身对照病例系列显示,排除暴露当日,COVID-19后第1周急性心梗发生率比(IRR)为2.89(95%CI 1.51-5.55),缺血性卒中IRR为2.97(95%CI 1.71-5.15);匹配队列分析排除第0天,COVID-19后2周内急性心梗OR为3.41(95%CI 1.58-7.36),卒中OR为3.63(95%CI 1.69-7.80)。作者认为COVID-19是急性心梗和缺血性卒中的危险因素,强调接种COVID-19疫苗的必要性。

要点

  • 排除暴露当日,COVID-19后第1周急性心梗IRR 2.89(95%CI 1.51-5.55),缺血性卒中IRR 2.97(95%CI 1.71-5.15)。
  • 排除暴露当日,COVID-19后第2周急性心梗IRR 2.53(95%CI 1.29-4.94),缺血性卒中IRR 2.80(95%CI 1.60-4.88)。
  • 匹配队列排除第0天,COVID-19后2周内急性心梗OR 3.41(95%CI 1.58-7.36),卒中OR 3.63(95%CI 1.69-7.80)。
  • 作者认为COVID-19是急性心梗和缺血性卒中的危险因素,并强调需要接种COVID-19疫苗。

适用人群与场景

  • 瑞典2020年2月1日至9月14日所有COVID-19患者86742例纳入自身对照病例系列分析。
  • 匹配队列研究纳入COVID-19患者及348481名按年龄、性别、居住县匹配的对照个体。

诊断标准与关键阈值

  • 通过国际疾病分类编码识别因急性心肌梗死或缺血性卒中住院的患者。

研究设计与关键结果

  • 自身对照病例系列:排除暴露当日,COVID-19后第1周急性心梗IRR 2.89(95%CI 1.51-5.55),第2周2.53(1.29-4.94),第3-4周1.60(0.84-3.04)。
  • 自身对照病例系列:包含暴露当日,COVID-19后第1周急性心梗IRR 8.44(5.45-13.08),第2周2.56(1.31-5.01),第3-4周1.62(0.85-3.09)。
  • 自身对照病例系列:排除暴露当日,COVID-19后第1周缺血性卒中IRR 2.97(1.71-5.15),第2周2.80(1.60-4.88),第3-4周2.10(1.33-3.32)。
  • 自身对照病例系列:包含暴露当日,COVID-19后第1周缺血性卒中IRR 6.18(4.06-9.42),第2周2.85(1.64-4.97),第3-4周2.14(1.36-3.38)。
  • 匹配队列分析:排除第0天,COVID-19后2周内急性心梗OR 3.41(1.58-7.36),缺血性卒中OR 3.63(1.69-7.80)。
  • 匹配队列分析:包含第0天,COVID-19后2周内急性心梗OR 6.61(3.56-12.20),缺血性卒中OR 6.74(3.71-12.20)。

证据类型、等级与局限

  • 研究类型:自身对照病例系列与匹配队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为COVID-19是急性心肌梗死和缺血性卒中的危险因素,急性心肌梗死和缺血性卒中构成COVID-19临床图景的一部分。
  • 作者强调需要接种COVID-19疫苗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: COVID-19 is a complex disease targeting many organs. Previous studies highlight COVID-19 as a probable risk factor for acute cardiovascular complications. We aimed to quantify the risk of acute myocardial infarction and ischaemic stroke associated with COVID-19 by analysing all COVID-19 cases in Sweden.

METHODS: This self-controlled case series (SCCS) and matched cohort study was done in Sweden. The personal identification numbers of all patients with COVID-19 in Sweden from Feb 1 to Sept 14, 2020, were identified and cross-linked with national inpatient, outpatient, cancer, and cause of death registers. The controls were matched on age, sex, and county of residence in Sweden. International Classification of Diseases codes for acute myocardial infarction or ischaemic stroke were identified in causes of hospital admission for all patients with COVID-19 in the SCCS and all patients with COVID-19 and the matched control individuals in the matched cohort study. The SCCS method was used to calculate the incidence rate ratio (IRR) for first acute myocardial infarction or ischaemic stroke following COVID-19 compared with a control period. The matched cohort study was used to determine the increased risk that COVID-19 confers compared with the background population of increased acute myocardial infarction or ischaemic stroke in the first 2 weeks following COVID-19.

FINDINGS: 86 742 patients with COVID-19 were included in the SCCS study, and 348 481 matched control individuals were also included in the matched cohort study. When day of exposure was excluded from the risk period in the SCCS, the IRR for acute myocardial infarction was 2·89 (95% CI 1·51-5·55) for the first week, 2·53 (1·29-4·94) for the second week, and 1·60 (0·84-3·04) in weeks 3 and 4 following COVID-19. When day of exposure was included in the risk period, IRR was 8·44 (5·45-13·08) for the first week, 2·56 (1·31-5·01) for the second week, and 1·62 (0·85-3·09) for weeks 3 and 4 following COVID-19. The corresponding IRRs for ischaemic stroke when day of exposure was excluded from the risk period were 2·97 (1·71-5·15) in the first week, 2·80 (1·60-4·88) in the second week, and 2·10 (1·33-3·32) in weeks 3 and 4 following COVID-19; when day of exposure was included in the risk period, the IRRs were 6·18 (4·06-9·42) for the first week, 2·85 (1·64-4·97) for the second week, and 2·14 (1·36-3·38) for weeks 3 and 4 following COVID-19. In the matched cohort analysis excluding day 0, the odds ratio (OR) for acute myocardial infarction was 3·41 (1·58-7·36) and for stroke was 3·63 (1·69-7·80) in the 2 weeks following COVID-19. When day 0 was included in the matched cohort study, the OR for acute myocardial infarction was 6·61 (3·56-12·20) and for ischaemic stroke was 6·74 (3·71-12·20) in the 2 weeks following COVID-19.

INTERPRETATION: Our findings suggest that COVID-19 is a risk factor for acute myocardial infarction and ischaemic stroke. This indicates that acute myocardial infarction and ischaemic stroke represent a part of the clinical picture of COVID-19, and highlights the need for vaccination against COVID-19.

FUNDING: Central ALF-funding and Base Unit ALF-Funding, Region Västerbotten, Sweden; Strategic funding during 2020 from the Department of Clinical Microbiology, Umeå University, Sweden; Stroke Research in Northern Sweden; The Laboratory for Molecular Infection Medicine Sweden.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study. Lancet. 2021. PMID: 34332652. doi:10.1016/S0140-6736(21)00896-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。